From: FiercePharma By: Fraiser Kansteiner In the aftermath of a surprise FDA rejection in chronic kidney disease, Ardelyx is...
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day...
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat,...
From: FiercePharma By: Beth Snyder Bulik The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with...
After several months on the market to treat lupus nephritis, uptake and prescribing patterns of Benlysta and Lupkynis reveal nephrologists...
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards...
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
Spherix announces the release of three new research publications in its RealWorld Dynamix™ series, revealing patient types, treatment paradigms, and...
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with...
According to new research published by Spherix Global Insights, the CKD non-dialysis market is poised for seismic shifts as SGLT2...
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...
